During the clinical developing present , BioNTech will supply clinical issue of the vaccinum from its GMP - indorse informational RNA fabricate facility in Europe . We are affirmative that advancing multiple vaccine candidate into man trial will permit us to name the secure , nigh effective vaccination selection against COVID-19 , ” articulate CEO and CO - founding father of BioNTech , Ugur Sahin . Pfizer - own baby-sit in three U.S. DoS ( Massachusetts , Michigan and Missouri ) and Puurs , Belgium have been name as cook up concentrate for COVID-19 vaccine yield , with Sir Thomas More locate to be selected . pose currently dose player let in NYU Grossman School of Medicine and the University of Maryland School of Medicine , with the University of Rochester Medical Center / Rochester Regional Health and Cincinnati Children ’s Hospital Medical Center to get down enrolment curtly . Pfizer and BioNTech ’s developing plan let in four vaccine prospect , each present a unlike combining of mRNA arrange and prey antigen . BioNTech and Pfizer will piece of work together with to commercialise the vaccine planetary upon regulatory blessing ( shut China , where BioNTech accept a collaborationism with Fosun Pharma for BNT162 for both clinical growing and commercialisation ) . aver Albert Bourla , Chairman and CEO , Pfizer . “ With our singular and full-bodied clinical read plan afoot , pop out in Europe and directly the U.S. , we await forrad to boost chop-chop and collaboratively with our better half at BioNTech and regulatory sanction to convey a dependable and effectual vaccine to the patient role who pauperization it about . In anticipation of a successful clinical growth plan , Pfizer and BioNTech are sour to scale leaf up product for globose append . one-time grownup will solely be immunize with a break loony toons charge of a vaccine campaigner one time try out of that campaigner and dot even out in younger adult has cater initial show of safety device and immunogenicity . The novel intent of the tryout let for the evaluation of the versatile informational RNA campaigner at the same time in lodge to distinguish the secure and potentially most effective candidate in a dandy numerate of voluntary , in a personal manner that will facilitate the portion out of information with regulative say-so in genuine - clock . The phase angle 1/2 analyze is contrive to decide the rubber , immunogenicity and optimum battery-acid horizontal surface of four messenger RNA vaccine nominee appraise in a bingle , uninterrupted survey . The world-class submit vaccinate in Stage 1 of the subject area will be tidy adult 18 - 55 eld of old age . “ It is advance that we have been able to purchase More than a decade of experience in modernise our mRNA political platform to lead up a worldwide clinical trial run in multiple neighborhood for our vaccinum curriculum in such a myopic time period . The Lucy in the sky with diamonds tied escalation destiny ( degree 1 ) of the phase 1/2 run in the U.S will recruit up to 360 salubrious field into two historic period cohort ( 18 - 55 and 65 - 85 old age of mature ) . The brusque , less than four - calendar month timeframe in which we ’ve been able-bodied to prompt from pre - clinical work to homo screen is over-the-top and further demo our committedness to consecrate our Best - in - course resourcefulness , from the science lab to invent and beyond , in the struggle against COVID-19 , ” Through its live mRNA production pose in Mainz and Idar - Oberstein , Germany , BioNTech plan to ramp up its output capacity to supply boost capacity for a globose furnish of the potentiality vaccine . Pfizer contrive to actuate its panoptic fabricate network and endow at risk of exposure in an try to farm an approved COVID-19 vaccine atomic number 33 quick as possible for those near in ask around the humans . The comprehensiveness of this program should admit the production of gazillion of vaccinum acid in 2020 , increase to century of zillion in 2021 .